USH1825H - Isothermal transcription based assay for the detection of HTLV I and HTLV II RNA - Google Patents
Isothermal transcription based assay for the detection of HTLV I and HTLV II RNA Download PDFInfo
- Publication number
- USH1825H USH1825H US09/015,876 US1587698A USH1825H US H1825 H USH1825 H US H1825H US 1587698 A US1587698 A US 1587698A US H1825 H USH1825 H US H1825H
- Authority
- US
- United States
- Prior art keywords
- seq
- htlv
- rna
- primers
- detection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000598436 Human T-cell lymphotropic virus Species 0.000 title claims abstract description 122
- 238000001514 detection method Methods 0.000 title claims abstract description 40
- 238000013518 transcription Methods 0.000 title claims abstract description 25
- 230000035897 transcription Effects 0.000 title claims abstract description 25
- 238000003556 assay Methods 0.000 title abstract description 20
- 239000000523 sample Substances 0.000 claims abstract description 60
- 230000003321 amplification Effects 0.000 claims abstract description 55
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 55
- 238000000034 method Methods 0.000 claims description 58
- 108091034117 Oligonucleotide Proteins 0.000 claims description 26
- 239000002773 nucleotide Substances 0.000 claims description 9
- 125000003729 nucleotide group Chemical group 0.000 claims description 9
- 238000009396 hybridization Methods 0.000 claims description 8
- 239000013615 primer Substances 0.000 claims 11
- 239000003155 DNA primer Substances 0.000 claims 2
- 108700026241 pX Genes Proteins 0.000 abstract description 7
- 101150027303 tax gene Proteins 0.000 abstract description 6
- 108700004026 gag Genes Proteins 0.000 abstract description 3
- 108700004029 pol Genes Proteins 0.000 abstract description 3
- 101150098622 gag gene Proteins 0.000 abstract description 2
- 101150088264 pol gene Proteins 0.000 abstract description 2
- 150000007523 nucleic acids Chemical class 0.000 description 52
- 108020004707 nucleic acids Proteins 0.000 description 51
- 102000039446 nucleic acids Human genes 0.000 description 51
- 108020004414 DNA Proteins 0.000 description 41
- 210000004027 cell Anatomy 0.000 description 40
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 39
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 230000035945 sensitivity Effects 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 14
- 239000000284 extract Substances 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- 238000003752 polymerase chain reaction Methods 0.000 description 11
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 8
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 8
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102100034343 Integrase Human genes 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 208000006961 tropical spastic paraparesis Diseases 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 4
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 101710137500 T7 RNA polymerase Proteins 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010044696 Tropical spastic paresis Diseases 0.000 description 3
- 108020000999 Viral RNA Proteins 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 238000011901 isothermal amplification Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 2
- 241000713838 Avian myeloblastosis virus Species 0.000 description 2
- 241000463291 Elga Species 0.000 description 2
- 241000701832 Enterobacteria phage T3 Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 208000007687 HTLV-II Infections Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 2
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 2
- 208000000816 Intravenous Substance Abuse Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 201000006966 adult T-cell leukemia Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 230000008823 permeabilization Effects 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 241000206761 Bacillariophyta Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 208000027814 HTLV-2 infection Diseases 0.000 description 1
- 208000005599 HTLV-I Infections Diseases 0.000 description 1
- 101000666730 Homo sapiens T-complex protein 1 subunit alpha Proteins 0.000 description 1
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000845082 Panama Species 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108010047320 Pepsinogen A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 241001468001 Salmonella virus SP6 Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 102000004598 Small Nuclear Ribonucleoproteins Human genes 0.000 description 1
- 108010003165 Small Nuclear Ribonucleoproteins Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 102100038410 T-complex protein 1 subunit alpha Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 240000002033 Tacca leontopetaloides Species 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010249 in-situ analysis Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- XKMLYUALXHKNFT-UHFFFAOYSA-N rGTP Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O XKMLYUALXHKNFT-UHFFFAOYSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 230000006648 viral gene expression Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2531/00—Reactions of nucleic acids characterised by
- C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
- C12Q2531/143—Promoter based amplification, e.g. NASBA, 3SR, TAS
Definitions
- the present invention is directed to an isothermal transcription based assay for the detection of HTLV I and HTLV II RNAs.
- the present invention is also directed to oligonucleotides for amplifying HTLV I and HTLV II RNA and probes for use in the detection of the amplification product.
- HTLV I Human T-cell lymphotropic virus type I
- ATLL T-cell leukemia/lymphoma
- HAM HTLV-associated myelopathy
- HTLV II human T-cell lymphotropic virus type II
- CFDS chronic fatigue immune dysfunction syndrome
- HTLV II infections are also distinct, being primarily associated with intravenous drug abuse and a focus of HTLV II endemicity has been reported among the native Guaymi Indians of Panama (Heneine et al, 1991, New Eng. J. Med. 324:565).
- RNA circulating viral genome
- PCR Polymerase chain reaction
- the isothermal method of the present invention for HTLV I and II provides an effective method of screening for the presence of several viral transcripts or viral genome and is able to distinguish between the two viruses.
- the present invention provides isothermal transcription based amplification assays for the detection of HTLV I and HTLV II viral RNAs.
- the detection assays use primer pairs and probes for each of two target regions in the tax gene, one target in the pol gene, and one target in the gag gene of HTLV I, and primer pairs and probes for each of two target regions in the tax gene of HTLV II.
- HTLV I NASBA assay tax, pol and gag transcripts were detected from patient peripheral blood mononuclear cells (PBMCS) and in an HTLV II NASBA assay, tax transcripts were detected from the same cells.
- PBMCS peripheral blood mononuclear cells
- An isothermal amplification method starts with an RNA template and alternately synthesizes DNA and RNA.
- an RNA template, reverse transcriptase, and an oligonucleotide referred to herein as a primer
- an RNA/DNA hybrid is generated.
- the RNA is degraded from the hybrid by the RNAse H activity.
- a double stranded DNA is then generated by the reverse transcriptase using another oligonucleotide (referred to herein as primer), and then the double stranded DNA is used as template for large amounts of RNA synthesis by the RNA polymerase.
- One of the primers has, in addition to the sequences complementary to the template, additional sequences necessary for generating an RNA polymerase promoter and transcription initiation site which can be used by the RNA polymerase.
- RNAse treatment prior to RT-PCR can be employed (Bitsch, A. et al., J. Infect Dis. 167, 740-743, 1993; Meyer, T. et al., Mol. Cell Probes, 8, 261-271, 1994), but sometimes fails to remove contaminating DNA sufficiently (Bitsch, A. et al., 1993).
- the purpose of applying such an assay would be to determine the presence and level of these transcripts, and to use these levels for the purpose of screening of blood donors, epidemiological studies, and in clinical practice for prognosis and/or therapeutic management.
- An isothermal transcription based assay is used for the detection of HTLV I and HTLV II viral RNA. Any isothermal transcription based assay may be used with the primers and probes of the present invention.
- the isothermal transcription based assay of the present invention is carried out under conditions that can be readily determined by a person of ordinary skill in the art.
- the preferred amplification method of the present invention is the isothermal transcription based amplification system referred to as NASBA.
- the NASBA method is disclosed in U.S. Pat. Nos. 5,409,818 and 5,554,527, which are herein incorporated by reference.
- NASBA includes the use of T7 RNA polymerase to transcribe multiple copies of RNA from a template including a T7 promoter.
- TAS transcription based amplification system
- TAS transcription based amplification system
- Transcription based amplification techniques usually comprise treating target nucleic acid with two oligonucleotides one of which comprises a promoter sequence, to generate a template including a functional promoter. Multiple copies of RNA are transcribed from said template and can serve as a basis for further amplification.
- EP 408295 is primarily concerned with a two-enzyme transcription based amplification method.
- Transcription based amplification methods such as the NASBA method described in EP 329822, are usually employed with a set of oligonucleotides, one of which is provided with a promoter sequence that is recognized by an enzyme with DNA dependent RNA polymerase activity such as, for example, T7 polymerase.
- a set of oligonucleotides one of which is provided with a promoter sequence that is recognized by an enzyme with DNA dependent RNA polymerase activity such as, for example, T7 polymerase.
- modifications of transcription based techniques are known in the art. These modifications comprise, for example, the use of blocked oligonucleotides (that may be provided with a promoter sequence). These oligos are blocked so as to inhibit an extension reaction proceeding therefrom (U.S. Pat. No.
- promoter-primers oligonucleotides provided with a promoter sequence
- transcription based amplification techniques optionally combined with the use of one or more oligonucleotides that are not provided with a promoter sequence.
- oligonucleotide refers to a molecule comprised of two or more deoxyribonucleotides or ribonucleotides. Such oligonucleotides may be used as primers and probes.
- analogues of oligonucleotides can also be prepared.
- Such analogues may comprise alternative structures such as "PNA” (molecules with a peptide-like backbone instead of the phosphate sugar backbone of normal nucleic acid) or the like.
- primer refers to an oligonucleotide which is capable of acting as a point of initiation of synthesis of a primer extension product which is complementary to a nucleic acid strand (template or target sequence) when placed under suitable conditions (e.g., buffer, salt, temperature and pH) in the presence of nucleotides and an agent for nucleic acid polymerization, such as DNA dependent or RNA dependent polymerase.
- a primer must be sufficiently long to prime the synthesis of extension products in the presence of an agent for polymerization.
- a typical primer contains at least 10 nucleotides in length of a sequence substantially complementary to the target sequence, but somewhat longer primers are preferred.
- primers usually contain about 15-26 nucleotides but longer primers may also be employed, especially when the primers contain additional sequences such as a promoter sequence for a particular polymerase. Primers may also contain linker sequences between the promoter sequence and the sequences complementary to the target sequence.
- a set of primers will consist of at least two primers, one "upstream” (P2) and one “downstream” (P1) primer which together define the amplificate (the sequence that will be amplified using said primers).
- P2 upstream
- P1 downstream
- One of the primers is understood to contain, in addition to sequences that will hybridize to the target sequence, sequences which provide promoter activity. Most often the P1 primer will include the promoter sequence.
- promoter sequence defines a region of a nucleic acid sequence that is specifically recognized by an RNA polymerase that binds to a recognized sequence and initiates the process of transcription by which an RNA transcript is produced.
- any promoter sequence may be employed for which there is a known and available polymerase that is capable of recognizing the initiation sequence.
- Known and useful promoters are those that are recognized by certain bacteriophage RNA polymerases such as bacteriophage T3, T7 or SP6. Their function as a primer, e.g., the starting point for an elongation reaction, however, may be blocked, as already mentioned above, or absent in some embodiments of transcription based amplification reactions.
- a particularly preferred promoter sequence is the sequence of the T7 RNA polymerase promoter, the sequence of which is as follows: AATTCTAATACGACTCACTATAGGG SEQ ID NO:29.
- SEQ ID NOs 3, 8, 12, 16, 21, 23, and 26 comprise the sequences of the specific target primer operably linked to the T7 promoter sequence, shown in italics. This makes the sequences especially suitable for use as a downstream primer in a transcription based amplification technique such as NASBA. However, the sequences for the T7 promoter shown in italics may be substituted by sequences of other promoters for use with other RNA polymerases.
- a preferred embodiment of the present invention is a combination of two oligonucleotides according to the invention, for use as a set in nucleic acid amplification.
- One of the oligonucleotides may serve as an "upstream oligonucleotide", i.e., upstream primer, while the second oligonucleotide serves as a "downstream oligonucleotide", i.e., downstream primer, in the amplification reaction.
- upstream oligonucleotide i.e., upstream primer
- downstream oligonucleotide i.e., downstream primer
- the reverse transcriptase activity is provided by avian myeloblastosis virus (AMV) reverse transcriptase and the RNA polymerase is provided by T7 RNA polymerase.
- AMV avian myeloblastosis virus
- the amplification method of the present invention may be applied to extracts of samples comprising nucleic acid, or whole cells or tissues for in situ amplification.
- the samples may be various body fluids, particularly blood, plasma, and serum, from humans.
- the samples may also be tissue samples from humans, for instance, lymph tissue.
- the sample may be total RNA extracts (such as those described in Chomczynski and Sacchi, Anal. Biochem.162:156, 1987 ) or "Boom" extracts (Boom et al, J. Clin. Micro.: 28, No.3, March 1990, p.495-503), which is herein incorporated by reference.
- the method is preferably applied to "Boom extracts".
- the amplificate is detected by hybridization with an appropriately labeled oligonucleotide probe.
- the label may contain a radioactive moiety, a detectable enzyme, or any other moiety capable of generating a detectable signal, such as a colorimetric, fluorescent, chemiluminescent or electrochemiluminescent (ECL) signal.
- ECL electrochemiluminescent
- the amplification products are resolved by agarose gel electrophoresis, then transferred to nylon membranes and hybridized to a probe that is 5'-end labeled with 32 P using standard methods. The products are then visualized by autoradiography.
- the amplification products can be detected using the ELGA.
- a probe that is specific for the amplification reaction product and conjugated at its 5' end with horseradish peroxidase (HRP) is hybridized to the amplification product.
- the hybridization product is then resolved electrophoretically on a polyacrylamide gel.
- a colorimetric enzyme reaction allows for the visualization of the reaction product in the gel.
- a third embodiment of the present invention makes use of electrochemiluminescence chemistry (or ECL).
- ECL electrochemiluminescence chemistry
- This embodiment uses a biotinylated capture probe immobilized onto the surface of a streptavidin-coated magnetic bead via the biotin-avidin interaction.
- This system also requires an oligonucleotide detector probe, which can hybridize to an independent region of the amplification product. This detector probe is labeled with Ruthenium, the substance that is responsible for generating an ECL signal.
- Each of the detection systems could use one or more internal controls to monitor the efficiency of the extraction process and the amplification assay itself.
- the detection systems are described in detail in Romano et al, DNA Technology 16:89-103 (1996), and van Gemen et al., J. of Virol. Methods, 49:157-168 (1994), which are herein incorporated by reference.
- Methods for internal controls are described in van Gemen et al, Reviews in Medical Virology, 5:205-211 (1995), which is herein incorporated by reference.
- the method is performed as follows.
- the cells are fixed and then permeabilized to optimize permeability of the cell membranes.
- the fixatives are those standardly used in the art for cell or tissue preparations, such as acetone and methanol, ethanol, formalin, formaldehyde, paraformaldehyde, or Permafix®, and the permeabilization is done by proteinases, such as proteinase K or pepsinogen.
- the cells are then washed to remove all reagents that might inhibit the transcription based reaction.
- Permeabilization is done to the point that the cells allow entry of all necessary amplification reaction components, yet retain the targets and amplification products within the cells.
- cosolvents such as glycerol or DMSO may be added to optimize the NASBA reaction.
- Detection of amplification products may be by direct labelling (with, for instance, biotin or digoxigenin--UTP) or by in situ hybridization with labelled probe.
- the direct labelling method requires that conditions can be optimized to remove unincorporated label while maintaining the amplification products.
- the isothermal transcription based amplification method is used in concert with a particular RNA extraction technique ("Boom extraction", Boom et al, J. Clin. Micro.: 28, No.3, March 1990, p.495-503), and ECL detection (electrochemiluminescence).
- RNA extraction technique Boom et al, J. Clin. Micro.: 28, No.3, March 1990, p.495-503
- ECL detection electro-hemiluminescence
- the advantages of the system are those associated with an amplification based assay capable of providing sequence level data. Although some of these same advantages exist for the RT-PCR (i.e., increased sensitivity over ELISA, gene sequence specificity), there are advantages of NASBA for RNA over RT-PCR.
- Boom extracts are purified preparations of DNA and RNA.
- the Boom method is based on the lysing and nuclease inactivating properties of the chaotropic agent guanidinium thiocyanate (GuSCN) together with the nucleic acid binding properties of silica particles or diatoms.
- GuSCN guanidinium thiocyanate
- nucleic acids including covalently closed circular, relaxed circular, linear double-stranded DNA, single stranded DNA, tRNA, mRNA, and rRNA, can be purified from a sample in less than one hour and recovered in the original reaction vessel.
- a small sample is pipetted into a reaction vessel containing a solid nucleic acid carrier and a GuSCN containing lysis buffer. Lysis of the cells occurs and the released nucleic acids bind to the carrier.
- the carrier-nucleic acid complexes can be separated by centrifugation. Several wash steps follow and the complexes are then dried.
- the nucleic acids are eluted in an aqueous low-salt buffer in the initial reaction vessel and used for the amplification reaction.
- amplification is achieved in a 20 ⁇ L reaction containing 5 ⁇ L of the nucleic acid extract material in 10 ⁇ L of premix [Tris (40 mM) pH8.5; MgCl 2 (12 mM); KCL (70 mM); DTT (5mM); dNTPs (each) (1 mM); rATP, rUTP, rCTP (2 mM); rGTP (1.5 mM); ITP (0.5 mM); DMSO (15%); P1 and P2, (0.2 ⁇ M); Sorbitol (1.5 M)].
- Tris 40 mM pH8.5; MgCl 2 (12 mM); KCL (70 mM); DTT (5mM); dNTPs (each) (1 mM); rATP, rUTP, rCTP (2 mM); rGTP (1.5 mM); ITP (0.5 mM); DMSO (15%); P1 and P2, (0.2 ⁇ M); Sorbito
- the method can be carried out as follows.
- the tops of the tubes may be spun.
- primers and probes were designed for the transcripts of the tax, pol, and gag genes of HTLV I and the tax gene of HTLV II.
- the primer and probe sequences were derived from the Genbank and/or Los Alamos data base for retroviruses entries for these genes.
- the primer and probe oligonucleotides are listed on Tables 1 and 2.
- the primer sets shown on Tables 1 and 2 were used in the following experiments.
- the primer set used for HTLV II tax A was set P2B/P1B in examples below.
- Sensitivity was assessed for each primer set by determining (1) the lowest number of chronically infected cells that are detectable, and (2) the least amount of total RNA obtained from chronically infected cell lines that is detectable.
- nucleic acids were extracted by the Boom method and amplification was by the standard NASBA method disclosed above using the indicated primer sets. Detection was by blot based 32 P detection outline above.
- nucleic acids were extracted by the Boom method and amplification was by the standard NASBA method disclosed above using the indicated primer sets. Detection was by blot based 32 P detection outline above. The nucleic acid equivalent from 4 ⁇ 10 4 cells went into each amplification reaction.
- PBMCs from 20 primary cultures were obtained from various HTLV I/HTLV II infected patients. These materials were collected and cryopreserved several years ago without regard for future analysis by amplification methodologies (The integrity of the RNA was confirmed by sn-RNP NASBA analysis). Boom RNA extractions of the samples were then tested with the HTLV I tax A primer set. Detection of the amplification products were by hybridization with 32 P, ELGA, or Ru 2+ . The results are shown in Table 7.
- primers have been developed using model systems such as in vitro transcribed RNA, virus stocks, or cells lines with very high expression of the target gene, but those primers were found to be nonfunctional when the target molecule is in a background of clinical samples.
- model systems such as in vitro transcribed RNA, virus stocks, or cells lines with very high expression of the target gene, but those primers were found to be nonfunctional when the target molecule is in a background of clinical samples.
- the exact mechanism underlying this problem is not understood, but is believed to arise due to the lower temperature of the NASBA reaction, which does not entirely melt secondary structure of the target molecule and/or allows nonspecific binding of primers to background nucleic acids in the sample. It is essential for the application of the NASBA system to clinical samples that the primers not be absorbed by background nucleic acids, but rather be available for specific binding to the target molecule.
- the HTLV I tax A primer set was able to amplify 5 pg of total RNA from these cells; the tax B and pol primers were able to amplify down to 500 pg and 5 ng, respectively.
- the difference in sensitivity for the two tax primer sets, which are specific for the same RNA molecule, indicates a primer based component to NASBA sensitivity. This is most likely due to secondary structure issues which are typical with RNA analytes.
- the two sets of primers may not be able to anneal to their respective targets with equal efficiency.
- non-preferred primers of the present invention are non-preferred for a NASBA method, such primers may be useful for other amplification methods such as polymerase chain reaction (PCR) or reverse transcription/polymerase chain reaction (RT/PCR).
- PCR polymerase chain reaction
- RT/PCR reverse transcription/polymerase chain reaction
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
An isothermal transcription based amplification assay for the detection of HTLV I RNA uses primers and probes for sequences within the tax gene, the pol gene, or the gag gene. An isothermal transcription based amplification assay for the detection of HTLV II uses primers and probes for sequences within the tax gene. Target specific primers and probes are also disclosed.
Description
The present invention is directed to an isothermal transcription based assay for the detection of HTLV I and HTLV II RNAs. The present invention is also directed to oligonucleotides for amplifying HTLV I and HTLV II RNA and probes for use in the detection of the amplification product.
Human T-cell lymphotropic virus type I (HTLV I) has been identified as the etiological agent responsible for adult T-cell leukemia/lymphoma (ATLL). It has also been associated with a chronic neurological disorder known as tropical spastic paraparesis (TSP) or HTLV-associated myelopathy (HAM) (Reitz et al., 1983, J. Infect. Dis. 147:399-405; Gessain et al., 1985, Lancet, ii:407-410). The virus can be transmitted by blood transfusion, intravenous drug abuse, sexual contact and through breast feeding, and infection is endemic in southwestern Japan, Central Africa, and in parts of the Caribbean. The virus has also been found in North America and Europe.
The closely related human T-cell lymphotropic virus type II (HTLV II) is not definitely implicated in human disease, although it has been identified in two cases of atypical hairy cell leukemia (Kalyanaraman et al, 1982, Science, 218:571-573), HTLV II-like sequences have been detected in patients with chronic fatigue immune dysfunction syndrome (CFIDS) (DeFreitas et al, Proc. Natl. Acad. Sci. USA 88:2922-2926,1991) and an HTLV II virus has been isolated from cultured T cells of a patient with pancytopenia (Kalyanaraman et al, The EMBO Journal 4:6:1455-1460, 1985). The epidemiology of HTLV II infections is also distinct, being primarily associated with intravenous drug abuse and a focus of HTLV II endemicity has been reported among the native Guaymi Indians of Panama (Heneine et al, 1991, New Eng. J. Med. 324:565).
There is no viremia throughout the course of infection with HTLV I or II, i.e., the circulating viral genome (i.e., RNA) cannot be detected. Polymerase chain reaction (PCR) has been shown to be capable of detecting proviral sequences and to distinguish between HTLV I and HTLV II proviruses (Tuke et al., J. Virological Methods, 40:163-174, 1992). While it is possible to detect the integrated provirus, it has been difficult to detect mRNA and therefore determine the role of viral gene expression in development and maintenance of the disease state. Screening of patient PBMC by RT/PCR has been used for the detection of the HTLV I tax transcript in the PBMC of asymptomatic patients as well as infected individuals displaying disease, but this assay did not detect HTLV II transcripts (Breneman et al, PNAS 89:3005-3009, 1992).
In view of the very different prognoses associated with HTLV I and HTLV II infection, it is important to be able to distinguish between the two viruses for the purposes of screening of blood donors, epidemiological studies, and routine clinical practice. Serological tests have been attempted, but because of high amino acid sequence homology, such tests have not been able to differentiate the two viruses with certainty (Kline et al, 1991, Lancet 337:30-33).
An isothermal amplification method for the detection of HTLV RNAs has not been described. The isothermal method of the present invention for HTLV I and II provides an effective method of screening for the presence of several viral transcripts or viral genome and is able to distinguish between the two viruses.
The present invention provides isothermal transcription based amplification assays for the detection of HTLV I and HTLV II viral RNAs. The detection assays use primer pairs and probes for each of two target regions in the tax gene, one target in the pol gene, and one target in the gag gene of HTLV I, and primer pairs and probes for each of two target regions in the tax gene of HTLV II. In an HTLV I NASBA assay, tax, pol and gag transcripts were detected from patient peripheral blood mononuclear cells (PBMCS) and in an HTLV II NASBA assay, tax transcripts were detected from the same cells.
An isothermal amplification method starts with an RNA template and alternately synthesizes DNA and RNA. Using an RNA template, reverse transcriptase, and an oligonucleotide (referred to herein as a primer), an RNA/DNA hybrid is generated. The RNA is degraded from the hybrid by the RNAse H activity. A double stranded DNA is then generated by the reverse transcriptase using another oligonucleotide (referred to herein as primer), and then the double stranded DNA is used as template for large amounts of RNA synthesis by the RNA polymerase. One of the primers has, in addition to the sequences complementary to the template, additional sequences necessary for generating an RNA polymerase promoter and transcription initiation site which can be used by the RNA polymerase.
One of the advantages of an isothermal transcription based amplification method, as compared to other amplification methods such as PCR, is that by being isothermal, it requires few manipulations by the experimenter. The method may be used on purified or semi-purified RNA extracts, or on cell or tissue samples with in situ amplification. In addition, if the sample contains both DNA and RNA, the use of the alternative procedure of RT/PCR requires a first step of DNAse treatment, or some method to distinguish the mRNA- and DNA-derived PCR products is necessary. DNAse treatment prior to RT-PCR can be employed (Bitsch, A. et al., J. Infect Dis. 167, 740-743, 1993; Meyer, T. et al., Mol. Cell Probes, 8, 261-271, 1994), but sometimes fails to remove contaminating DNA sufficiently (Bitsch, A. et al., 1993).
The purpose of applying such an assay would be to determine the presence and level of these transcripts, and to use these levels for the purpose of screening of blood donors, epidemiological studies, and in clinical practice for prognosis and/or therapeutic management.
An isothermal transcription based assay is used for the detection of HTLV I and HTLV II viral RNA. Any isothermal transcription based assay may be used with the primers and probes of the present invention. The isothermal transcription based assay of the present invention is carried out under conditions that can be readily determined by a person of ordinary skill in the art.
The preferred amplification method of the present invention is the isothermal transcription based amplification system referred to as NASBA. The NASBA method is disclosed in U.S. Pat. Nos. 5,409,818 and 5,554,527, which are herein incorporated by reference. NASBA includes the use of T7 RNA polymerase to transcribe multiple copies of RNA from a template including a T7 promoter.
Another technique for the amplification of nucleic acid is the so-called transcription based amplification system (TAS). The TAS method is described in International Patent Application No. WO 88/10315. Transcription based amplification techniques usually comprise treating target nucleic acid with two oligonucleotides one of which comprises a promoter sequence, to generate a template including a functional promoter. Multiple copies of RNA are transcribed from said template and can serve as a basis for further amplification.
Other transcription based amplification techniques are described in EP 408295. EP 408295 is primarily concerned with a two-enzyme transcription based amplification method. Transcription based amplification methods, such as the NASBA method described in EP 329822, are usually employed with a set of oligonucleotides, one of which is provided with a promoter sequence that is recognized by an enzyme with DNA dependent RNA polymerase activity such as, for example, T7 polymerase. Several modifications of transcription based techniques are known in the art. These modifications comprise, for example, the use of blocked oligonucleotides (that may be provided with a promoter sequence). These oligos are blocked so as to inhibit an extension reaction proceeding therefrom (U.S. Pat. No. 5,554,516). One or more "promoter-primers" (oligonucleotides provided with a promoter sequence) may be used in transcription based amplification techniques, optionally combined with the use of one or more oligonucleotides that are not provided with a promoter sequence.
The term "oligonucleotide" as used herein refers to a molecule comprised of two or more deoxyribonucleotides or ribonucleotides. Such oligonucleotides may be used as primers and probes.
Of course, based on the sequences of the oligonucleotides of the present invention, analogues of oligonucleotides can also be prepared. Such analogues may comprise alternative structures such as "PNA" (molecules with a peptide-like backbone instead of the phosphate sugar backbone of normal nucleic acid) or the like.
The term "primer" as used herein refers to an oligonucleotide which is capable of acting as a point of initiation of synthesis of a primer extension product which is complementary to a nucleic acid strand (template or target sequence) when placed under suitable conditions (e.g., buffer, salt, temperature and pH) in the presence of nucleotides and an agent for nucleic acid polymerization, such as DNA dependent or RNA dependent polymerase. A primer must be sufficiently long to prime the synthesis of extension products in the presence of an agent for polymerization. A typical primer contains at least 10 nucleotides in length of a sequence substantially complementary to the target sequence, but somewhat longer primers are preferred. Usually primers contain about 15-26 nucleotides but longer primers may also be employed, especially when the primers contain additional sequences such as a promoter sequence for a particular polymerase. Primers may also contain linker sequences between the promoter sequence and the sequences complementary to the target sequence.
Normally a set of primers will consist of at least two primers, one "upstream" (P2) and one "downstream" (P1) primer which together define the amplificate (the sequence that will be amplified using said primers). One of the primers is understood to contain, in addition to sequences that will hybridize to the target sequence, sequences which provide promoter activity. Most often the P1 primer will include the promoter sequence.
The term "promoter sequence" defines a region of a nucleic acid sequence that is specifically recognized by an RNA polymerase that binds to a recognized sequence and initiates the process of transcription by which an RNA transcript is produced. In principle, any promoter sequence may be employed for which there is a known and available polymerase that is capable of recognizing the initiation sequence. Known and useful promoters are those that are recognized by certain bacteriophage RNA polymerases such as bacteriophage T3, T7 or SP6. Their function as a primer, e.g., the starting point for an elongation reaction, however, may be blocked, as already mentioned above, or absent in some embodiments of transcription based amplification reactions. A particularly preferred promoter sequence is the sequence of the T7 RNA polymerase promoter, the sequence of which is as follows: AATTCTAATACGACTCACTATAGGG SEQ ID NO:29.
SEQ ID NOs 3, 8, 12, 16, 21, 23, and 26 comprise the sequences of the specific target primer operably linked to the T7 promoter sequence, shown in italics. This makes the sequences especially suitable for use as a downstream primer in a transcription based amplification technique such as NASBA. However, the sequences for the T7 promoter shown in italics may be substituted by sequences of other promoters for use with other RNA polymerases.
A preferred embodiment of the present invention is a combination of two oligonucleotides according to the invention, for use as a set in nucleic acid amplification.
One of the oligonucleotides may serve as an "upstream oligonucleotide", i.e., upstream primer, while the second oligonucleotide serves as a "downstream oligonucleotide", i.e., downstream primer, in the amplification reaction.
Preferably, the reverse transcriptase activity is provided by avian myeloblastosis virus (AMV) reverse transcriptase and the RNA polymerase is provided by T7 RNA polymerase.
One of the advantages of an isothermal transcription based amplification method, as compared to other amplification methods such as PCR, is that by being isothermal, it requires few manipulations by the experimenter. However, the absence of a high temperature step does make it somewhat more difficult to find appropriate primers (see below).
The amplification method of the present invention may be applied to extracts of samples comprising nucleic acid, or whole cells or tissues for in situ amplification. The samples may be various body fluids, particularly blood, plasma, and serum, from humans. The samples may also be tissue samples from humans, for instance, lymph tissue.
If the method is applied to extracts of samples comprising nucleic acids, the sample may be total RNA extracts (such as those described in Chomczynski and Sacchi, Anal. Biochem.162:156, 1987 ) or "Boom" extracts (Boom et al, J. Clin. Micro.: 28, No.3, March 1990, p.495-503), which is herein incorporated by reference. The method is preferably applied to "Boom extracts".
The amplificate is detected by hybridization with an appropriately labeled oligonucleotide probe. The label may contain a radioactive moiety, a detectable enzyme, or any other moiety capable of generating a detectable signal, such as a colorimetric, fluorescent, chemiluminescent or electrochemiluminescent (ECL) signal. Blot based hybridization analysis and liquid hybridization based ECL analysis are preferably used, although other analysis systems such as ELGA (enzyme-linked gel assay) and in situ hybridization can also be used.
In one embodiment of the present invention, the amplification products are resolved by agarose gel electrophoresis, then transferred to nylon membranes and hybridized to a probe that is 5'-end labeled with 32 P using standard methods. The products are then visualized by autoradiography.
In a second embodiment of the present invention, the amplification products can be detected using the ELGA. In this method a probe that is specific for the amplification reaction product and conjugated at its 5' end with horseradish peroxidase (HRP) is hybridized to the amplification product. The hybridization product is then resolved electrophoretically on a polyacrylamide gel. A colorimetric enzyme reaction allows for the visualization of the reaction product in the gel.
A third embodiment of the present invention makes use of electrochemiluminescence chemistry (or ECL). This embodiment uses a biotinylated capture probe immobilized onto the surface of a streptavidin-coated magnetic bead via the biotin-avidin interaction. This system also requires an oligonucleotide detector probe, which can hybridize to an independent region of the amplification product. This detector probe is labeled with Ruthenium, the substance that is responsible for generating an ECL signal.
Each of the detection systems could use one or more internal controls to monitor the efficiency of the extraction process and the amplification assay itself. The detection systems are described in detail in Romano et al, DNA Technology 16:89-103 (1996), and van Gemen et al., J. of Virol. Methods, 49:157-168 (1994), which are herein incorporated by reference. Methods for internal controls are described in van Gemen et al, Reviews in Medical Virology, 5:205-211 (1995), which is herein incorporated by reference.
It may also be relevant to adapt the assay for an in situ format, which would be useful in pathology studies of tissue, particularly for lymphatic tissues. If the method is to be practiced on fixed preparations for in situ analysis, the method is performed as follows. The cells are fixed and then permeabilized to optimize permeability of the cell membranes. The fixatives are those standardly used in the art for cell or tissue preparations, such as acetone and methanol, ethanol, formalin, formaldehyde, paraformaldehyde, or Permafix®, and the permeabilization is done by proteinases, such as proteinase K or pepsinogen. The cells are then washed to remove all reagents that might inhibit the transcription based reaction. Permeabilization is done to the point that the cells allow entry of all necessary amplification reaction components, yet retain the targets and amplification products within the cells. In addition, cosolvents such as glycerol or DMSO may be added to optimize the NASBA reaction.
Detection of amplification products may be by direct labelling (with, for instance, biotin or digoxigenin--UTP) or by in situ hybridization with labelled probe. The direct labelling method requires that conditions can be optimized to remove unincorporated label while maintaining the amplification products.
In a particularly preferred embodiment of the present invention, the isothermal transcription based amplification method is used in concert with a particular RNA extraction technique ("Boom extraction", Boom et al, J. Clin. Micro.: 28, No.3, March 1990, p.495-503), and ECL detection (electrochemiluminescence). The advantages of the system are those associated with an amplification based assay capable of providing sequence level data. Although some of these same advantages exist for the RT-PCR (i.e., increased sensitivity over ELISA, gene sequence specificity), there are advantages of NASBA for RNA over RT-PCR. These include isothermal amplification, incorporation of reverse transcription into the amplification process, generation of a single-stranded product for purposes of detection by hybridization, application to wider array of specimen types (via Boom extract), and the sensitivity and dynamic range of the ECL detection.
Boom extracts are purified preparations of DNA and RNA. The Boom method is based on the lysing and nuclease inactivating properties of the chaotropic agent guanidinium thiocyanate (GuSCN) together with the nucleic acid binding properties of silica particles or diatoms. By using size fractionated silica particles, nucleic acids, including covalently closed circular, relaxed circular, linear double-stranded DNA, single stranded DNA, tRNA, mRNA, and rRNA, can be purified from a sample in less than one hour and recovered in the original reaction vessel.
A small sample is pipetted into a reaction vessel containing a solid nucleic acid carrier and a GuSCN containing lysis buffer. Lysis of the cells occurs and the released nucleic acids bind to the carrier. The carrier-nucleic acid complexes can be separated by centrifugation. Several wash steps follow and the complexes are then dried. The nucleic acids are eluted in an aqueous low-salt buffer in the initial reaction vessel and used for the amplification reaction.
In a preferred embodiment of the present invention, amplification is achieved in a 20 μL reaction containing 5 μL of the nucleic acid extract material in 10 μL of premix [Tris (40 mM) pH8.5; MgCl2 (12 mM); KCL (70 mM); DTT (5mM); dNTPs (each) (1 mM); rATP, rUTP, rCTP (2 mM); rGTP (1.5 mM); ITP (0.5 mM); DMSO (15%); P1 and P2, (0.2 μM); Sorbitol (1.5 M)]. This is then added to 5 μL of enzyme mix [BSA (2.1 μg/NASBA); RNase H (0.08 unit/NASBA); T7 RNA Polymerase (32 units/NASBA); and AMV-RT (6.4 units/NASBA)]. (The enzyme mixture must not be vortexed). If the nucleic acid sample decreases (5 μl), then the water volume increases accordingly so that the total volume stays 15 μl when the nucleic acid is added.
(It has been determined that the preferred method of the invention for the detection of the HTLV I gag transcript uses a premix with 42 mM KCL, rather than the 70 mM KCL preferred for the other targets and primer sets.)
The method can be carried out as follows.
1. Mix premix.
2. Add 10 μl of premix to 5 μl of nucleic acid in an Eppendorf tube.
3. Incubate at 65° C. for 5 minutes.
4. Transfer to 41° C. heat block, incubate for 5 minutes.
5. Add 5 μl of enzyme mix.
6. Mix without vortexing.
7. Incubate at 41° C. for 5 minutes.
8. If the tops of the tubes have condensation from the cooling, they may be spun.
9. Incubate at 41° C. for 90 minutes.
10. Spin down samples and store at -20° C.
In the method of the present invention primers and probes were designed for the transcripts of the tax, pol, and gag genes of HTLV I and the tax gene of HTLV II.
The primer and probe sequences were derived from the Genbank and/or Los Alamos data base for retroviruses entries for these genes.
The primer and probe oligonucleotides are listed on Tables 1 and 2.
TABLE 1
__________________________________________________________________________
HTLV-I Oligonucleotides
Oligo (Map Site*)
Sequence (all listed 5' to 3')
__________________________________________________________________________
HTLV I tax A
P2A (7372-7396)
ACGTGTTTGGAGACTGTGTACAAGG SEQ ID NO:1
P1A (7522-7543)
AGTCGAGGGATAAGGAACTGTA SEQ ID NO:2
P1A* AATTCTAATACGACTCACTATAGGGAGTCGAGGGA
TAAGGAACTGTA SEQ ID NO:3
DETECTION PROBE
(7426-7450)
GTTCGGCCCGCCTACATCGTCACGC SEQ ID NO:4
CAPTURE PROBE
(7485-7509)
TGGGACCCCATCGATGGACGCGTTA SEQ ID NO:5
HTLV I tax B
P2A (7828-7852)
ACGTGATTTTTTGCCACCCCGGCCA SEQ ID NO:6
P1A (8007-8031)
GGAACGGAAGGAGGCCGTTTTGCCA SEQ ID NO:7
P1A* AATTCTAATACGACTCACTATAGGGGGAACGGAAG
GAGGCCGTTTTGCCA SEQ ID NO:8
DETECTION PROBE
(7925-7949)
AGGGGCCCTAATAATTCTACCCGAA SEQ ID NO:9
HTLV I pol
P2A (4724-4752)
ACCTCCCTTGCTATTCGCCATACCACCCA SEQ ID NO:10
P1A (4953-4981)
GAGGGAACGTGTCTCTGGGATCGGCTGGA SEQ ID NO:11
P1A* AATTCTAATACGACTCACTATAGGGGAGGGAACGT
GTCTCTGGGATCGGCTGGA SEQ ID NO:12
DETECTION PROBE
(4883-4907)
ACAATCAACCACCTGAATGTGTTAA SEQ ID NO:13
HTLV I gag
P2A (1263-1287)
TGAAAGACCTACAGGCCATTAAGCA SEQ ID NO:14
P1A (1386-1406)
AGGAGCAAAGGTACTGCAGGA SEQ ID NO:15
P1A* AATTCTAATACGACTCACTATAGGGAGGAGCAAAG
GTACTGCAGGA SEQ ID NO:16
DETECTION PROBE
(1352-1375)
CAGTTTGACCCCAC(T/C)GCCAA(A/G)GAC SEQ ID
__________________________________________________________________________
NO:17
(the bases in parentheses represent mixed sites)
TABLE 2
__________________________________________________________________________
HTLV II Oligonucleotides
Oligo (Map Site*)
Sequence (all listed 5' to 3')
__________________________________________________________________________
HTLV II tax A
P2A (7248-7267)
TGGATACCCCGTCTACGTGT SEQ ID NO:18
P2B (7269-7288)
TGGCGATTGTGTACAGGCCG SEQ ID NO:19
P1A (7368-7387)
CGATGGGGTCCCAGGTGAGT SEQ ID NO:20
P1A* AATTCTAATACGACTCACTATAGGGCGATGGGGTCCCAGGTGAGT
SEQ ID NO:21
P1B (7390-7407)
AGAGCTGACAACGCGTCC SEQ ID NO:22
P1B* AATTCTAATACGACTCACTATAGGGAGAGCTGACAACGCGTCC
SEQ ID NO:23
PROBE (7316-7340)
GTTCCACCCGCCTACATCGACATGC SEQ ID NO:24
HTLV II tax B
P1 (7840-7864)
GGAACATTGTGGTGGGTAGGTCGTC SEQ ID NO:25
P1A* AATTCTAATACGACTCACTATAGGGAGAGGGAACATTGTGGTGGGTA
GGTCGTC SEQ ID NO:26
P2 (7658-7682)
CCGTAGTATGCCTATACCTATACCA SEQ ID NO:27
PROBE (7801-7825)
ATGTTCCTACACACAGGGACAGTCA SEQ ID NO:28
__________________________________________________________________________
*Position 1 is the first base in the genomic map of each virus.
Example 1--Initial Evaluation of Oligonucleotides
A. Sensitivity Evaluation
The primer sets shown on Tables 1 and 2 were used in the following experiments. The primer set used for HTLV II tax A was set P2B/P1B in examples below.
Sensitivity was assessed for each primer set by determining (1) the lowest number of chronically infected cells that are detectable, and (2) the least amount of total RNA obtained from chronically infected cell lines that is detectable.
For the cell sensitivity experiments, nucleic acids were extracted by the Boom method and amplification was by the standard NASBA method disclosed above using the indicated primer sets. Detection was by blot based 32 P detection outline above.
For the total RNA sensitivity experiments, RNA was extracted by the Chomczynski and Sacchi method and amplification was by the standard NASBA method disclosed above using the indicated primer sets. Detection was by blot based 32 P detection outline above.
The results are summarized in Tables 3 and 4, respectively.
TABLE 3
______________________________________
CELL SENSITIVITY
Cell Equivalent
Primer Set MT2 MoT
______________________________________
HTLV I tax A 0.4 cells
-
HTLV I tax B 40 cells
-
HTLV I pol 40 cells
-
HTLV I gag ND ND
HTLV II tax A - 5 cells
HTLV II tax B - 50 cells
______________________________________
- negative at 4000 cells for MT2 and at 5000 cells for MoT
*A1 ml aliquot of MT2 (8 × 10.sup.5 cells/ml) and MoT (1 ×
10.sup.6 cells/ml) were lysed in 9 mls GuSCN lysis buffer pH 6.8. The Boo
extraction method was used to isolate the nucleic acid, using 70 ul silic
and eluting in 100 ul of dH.sub.2 O.
TABLE 4 ______________________________________ TOTAL RNA SENSITIVITY Primer Set MT2 MoT ______________________________________ HTLV I tax A 5 pg - HTLV I tax B 500 pg - HTLV I pol 5 ng - HTLV I gag 500 pg - HTLV II tax A - 50 pg HTLV II tax B - 50 pg ______________________________________ - negative at 5 ng MoT
Results from this analysis indicate that the greatest sensitivity among the HTLV I primer sets was achieved with the HTLV I tax A primers. This finding was confirmed at the cellular as well as the RNA levels. However, it should be noted that these experiments were conducted with extracts from chronically infected cells and the apparent sensitivity could simply be a reflection of specific tax transcript expression in those cells. The two primer sets developed for HTLV II were for different sites within the tax gene. Interestingly, the tax A and B primer sets were not equally sensitive, suggesting a specific target sequence effect on sensitivity. Cell sensitivity experiments indicated that fewer cells are detectable with the HTLV II tax A primers, however total RNA results were the same for both primer sets. Therefore there is probably very little difference in the sensitivity capabilities of these two HTLV II tax primer sets.
B. Specificity
Specificity experiments were conducted using a constant amount of total RNA obtained from different cell lines that were chronically infected with various retroviruses.
For the cell specificity experiments, nucleic acids were extracted by the Boom method and amplification was by the standard NASBA method disclosed above using the indicated primer sets. Detection was by blot based 32 P detection outline above. The nucleic acid equivalent from 4×104 cells went into each amplification reaction.
For the total RNA specificity experiments, RNA was extracted by the Chomczynski and Sacchi method and amplification was by the standard NASBA method disclosed above using the indicated primer sets. 5 ng Total RNA/rxn was used. Detection was by blot based 32 P detection outline above.
The results are shown on Tables 5 and 6.
TABLE 5
______________________________________
CELL SPECIFICITY
silica extraction
H9 H9 of cells
Primer Set
MT2 MoT + - WATER
______________________________________
HTLV I + - - - -
tax A
Elga only
HTLV I* +/- - - - -
tax B
HTLV I + - - - -
pol A
HTLV I ND ND ND ND ND
gag
HTLV II - + - - -
tax A
HTLV II - + - - -
tax B
HIV-1 - - - + -
gag-3
Elga only
______________________________________
Note: Used 5 ul of 8 × 10.sup.3 /ul MT2 cell equivalents and 4 ul o
1 × 10.sup.4 /ul cell equivalents MoT, H9+, and H9-; all detections
by .sup.32 P labeled probe except where noted
*poor amplification trial
+ is positive, - is negative, and -/+ is weakly positive
TABLE 6
______________________________________
TOTAL RNA SPECIFICITY
Primer Set
MT2 MoT NS-1 H9+ H9- WATER
______________________________________
HTLV I + - + - - -
tax A
HTLV I + - + - - -
tax B
HTLV I + - - - - -
pol A
HTLV I ND ND ND ND ND ND
gag
HTLV II +* + - - - -
tax A
HTLV II ND ND ND ND ND ND
tax B
HIV-1 - - - + - -
gag-3
ELGA
______________________________________
Note: All detections by .sup.32 P labeled probe except where noted
*Very weakly positive
+ is positive, - is negative, and -/+ is weakly positive
A high degree of specificity was exhibited by all of the HTLV I primer sets using total RNA (5 ng/rxn) as well as cell extracts. However, variable results were obtained with the HTLV II primer sets. Although the HTLV II tax B primer set exhibited specific reactivity, there was evidence of cross reactivity with the HTLV II tax A primers.
Example 2--Testing of Patient Samples
Clinical samples were examined with the methods of the present invention. Initially, PBMCs from 20 primary cultures were obtained from various HTLV I/HTLV II infected patients. These materials were collected and cryopreserved several years ago without regard for future analysis by amplification methodologies (The integrity of the RNA was confirmed by sn-RNP NASBA analysis). Boom RNA extractions of the samples were then tested with the HTLV I tax A primer set. Detection of the amplification products were by hybridization with 32 P, ELGA, or Ru2+. The results are shown in Table 7.
TABLE 7
______________________________________
Patent ID
NSUH NASBA HTLV I
Disease
______________________________________
Ca* HTLV I -/+ asympto.
Gas HTLV I + ATL
La HTLV I + TSP/HIV-1
Fl HTLV I + ATL
Che HTLV I -/+ CLL
Do HTLV I + ATL
Sp** HTLV I - TSP
Ba HTLV I + asympto.
Ha HTLV I + CLL/HIV-1
Re HTLV I + asympto.
L78 HTLV I + asympto.
L97 HTLV I + asympto
Da HTLV II + none
Fly HTLV II -/+ none
Gar HTLV II + HIV-1
Fu HTLV II - none
St HTLV II - HIV-1
Cha HTLV II - HIV-1
Pa HTLV II - none
We HTLV II - HIV-1
______________________________________
*Patient Ca was originally diagnosed as HTLV I infected, but there is
reason to believe that this patient may actually be HTLV II positive
**Patient Sp was negative for snRNP RNA; all other samples were positive
for this control of RNA quality.
+ is positive, - is negative, and -/+ is weakly positive
The results indicated that all of the HTLV I positive patients were positive by HTLV I tax A NASBA.
Further, all except three of the HTLV II positive patients were negative with the HTLV I tax A primer set. It was suspected that the positive results obtained with the HTLV II samples were due to contamination of the original sample material. Experiments with chronically infected cell lines failed to show cross reactivity, and the level of HTLV II RNA is assumed to be high in such cell lines.
Nine additional samples from the same patient set were then obtained. Seven of the nine were positive for sn-RNP NASBA, and were the ones used for additional experiments. Of these seven, only one tested positive for HTLV I using the tax A primer set and probe (data not shown). This was the only sample of the seven which was previously known to be HTLV I positive.
Some of the samples from the original 20 patient specimens were then tested with some of the other primer sets developed in the present invention. Boom RNA extracts of these samples were tested in the standard NASBA assay. These results are shown on Table 8.
Excellent specificity was demonstrated for each for the HTLV I primer sets. Two of the HTLV II specimens in the original group which were shown to be HTLV I tax A positive were included in subpanel 2. These samples were negative in this repeat analysis with the HTLV I tax A primer set.
These experiments also demonstrated that each of the RNA analytes targeted by the individual primer sets could be used to detect viral RNA in patient samples. It appears that the HTLV II tax B primer set may have higher specificity.
TABLE 8
______________________________________
PATIENT PANEL STUDY
Fl Fu Ha Re We Da Gar La Vi
I II I I II II II I II
______________________________________
HTLVI + - + + - - - + -
tax A
HTLVI + - + + - - - + -
tax B
HTLVI + - + + - - - + -
pol
HTLVI ND ND ND ND ND ND ND ND ND
gag
HTLVII
+ + + + + - + - +
tax A
HTLVII
ND ND ND ND ND -, +"
+, -"
-, -"
+, +"
tax B
______________________________________
*Results from duplicate analysis due to poor assay performance
The biggest problem encountered in the development of NASBA assays is the selection of primers. It has often been the case that primers selected from sequence data, and meeting all the known requirements for primers, do not actually function in practice. In addition, in some cases primers have been developed using model systems such as in vitro transcribed RNA, virus stocks, or cells lines with very high expression of the target gene, but those primers were found to be nonfunctional when the target molecule is in a background of clinical samples. The exact mechanism underlying this problem is not understood, but is believed to arise due to the lower temperature of the NASBA reaction, which does not entirely melt secondary structure of the target molecule and/or allows nonspecific binding of primers to background nucleic acids in the sample. It is essential for the application of the NASBA system to clinical samples that the primers not be absorbed by background nucleic acids, but rather be available for specific binding to the target molecule.
The HTLV I tax A primer set was able to amplify 5 pg of total RNA from these cells; the tax B and pol primers were able to amplify down to 500 pg and 5 ng, respectively. The difference in sensitivity for the two tax primer sets, which are specific for the same RNA molecule, indicates a primer based component to NASBA sensitivity. This is most likely due to secondary structure issues which are typical with RNA analytes. Despite the fact that the same number of target molecules are present for the tax A and B primer sets, the two sets of primers may not be able to anneal to their respective targets with equal efficiency.
Even though the non-preferred primers of the present invention are non-preferred for a NASBA method, such primers may be useful for other amplification methods such as polymerase chain reaction (PCR) or reverse transcription/polymerase chain reaction (RT/PCR).
__________________________________________________________________________
# SEQUENCE LISTING
- (1) GENERAL INFORMATION:
- (iii) NUMBER OF SEQUENCES: 28
- (2) INFORMATION FOR SEQ ID NO:1:
- (i) SEQUENCE CHARACTERISTICS:
#pairs (A) LENGTH: 25 base
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
# 25 TGTA CAAGG
- (2) INFORMATION FOR SEQ ID NO:2:
- (i) SEQUENCE CHARACTERISTICS:
#pairs (A) LENGTH: 22 base
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
# 22CTG TA
- (2) INFORMATION FOR SEQ ID NO:3:
- (i) SEQUENCE CHARACTERISTICS:
#pairs (A) LENGTH: 47 base
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
# 47ACTA TAGGGAGTCG AGGGATAAGG AACTGTA
- (2) INFORMATION FOR SEQ ID NO:4:
- (i) SEQUENCE CHARACTERISTICS:
#pairs (A) LENGTH: 25 base
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
# 25 TCGT CACGC
- (2) INFORMATION FOR SEQ ID NO:5:
- (i) SEQUENCE CHARACTERISTICS:
#pairs (A) LENGTH: 25 base
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:
# 25 GACG CGTTA
- (2) INFORMATION FOR SEQ ID NO:6:
- (i) SEQUENCE CHARACTERISTICS:
#pairs (A) LENGTH: 25 base
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:
# 25 CCCC GGCCA
- (2) INFORMATION FOR SEQ ID NO:7:
- (i) SEQUENCE CHARACTERISTICS:
#pairs (A) LENGTH: 25 base
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:
# 25 GTTT TGCCA
- (2) INFORMATION FOR SEQ ID NO:8:
- (i) SEQUENCE CHARACTERISTICS:
#pairs (A) LENGTH: 50 base
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:
# 50TCACTA TAGGGGGAAC GGAAGGAGGC CGTTTTGCCA
- (2) INFORMATION FOR SEQ ID NO:9:
- (i) SEQUENCE CHARACTERISTICS:
#pairs (A) LENGTH: 25 base
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:
# 25 CTAC CCGAA
- (2) INFORMATION FOR SEQ ID NO:10:
- (i) SEQUENCE CHARACTERISTICS:
#pairs (A) LENGTH: 29 base
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:
# 29 GCCA TACCACCCA
- (2) INFORMATION FOR SEQ ID NO:11:
- (i) SEQUENCE CHARACTERISTICS:
#pairs (A) LENGTH: 29 base
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:
# 29 GGGA TCGGCTGGA
- (2) INFORMATION FOR SEQ ID NO:12:
- (i) SEQUENCE CHARACTERISTICS:
#pairs (A) LENGTH: 54 base
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:
- AATTCTAATA CGACTCACTA TAGGGGAGGG AACGTGTCTC TGGGATCGGC TG - #GA
54
- (2) INFORMATION FOR SEQ ID NO:13:
- (i) SEQUENCE CHARACTERISTICS:
#pairs (A) LENGTH: 25 base
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:
# 25 ATGT GTTAA
- (2) INFORMATION FOR SEQ ID NO:14:
- (i) SEQUENCE CHARACTERISTICS:
#pairs (A) LENGTH: 25 base
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:
# 25 CATT AAGCA
- (2) INFORMATION FOR SEQ ID NO:15:
- (i) SEQUENCE CHARACTERISTICS:
#pairs (A) LENGTH: 21 base
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:
#21 CAGG A
- (2) INFORMATION FOR SEQ ID NO:16:
- (i) SEQUENCE CHARACTERISTICS:
#pairs (A) LENGTH: 46 base
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:
# 46CTA TAGGGAGGAG CAAAGGTACT GCAGGA
- (2) INFORMATION FOR SEQ ID NO:17:
- (i) SEQUENCE CHARACTERISTICS:
#pairs (A) LENGTH: 24 base
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:
# 24CCAA RGAC
- (2) INFORMATION FOR SEQ ID NO:18:
- (i) SEQUENCE CHARACTERISTICS:
#pairs (A) LENGTH: 20 base
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:
# 20 GTGT
- (2) INFORMATION FOR SEQ ID NO:19:
- (i) SEQUENCE CHARACTERISTICS:
#pairs (A) LENGTH: 20 base
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:
# 20 GCCG
- (2) INFORMATION FOR SEQ ID NO:20:
- (i) SEQUENCE CHARACTERISTICS:
#pairs (A) LENGTH: 20 base
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:
# 20 GAGT
- (2) INFORMATION FOR SEQ ID NO:21:
- (i) SEQUENCE CHARACTERISTICS:
#pairs (A) LENGTH: 45 base
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:
#45 ACTA TAGGGCGATG GGGTCCCAGG TGAGT
- (2) INFORMATION FOR SEQ ID NO:22:
- (i) SEQUENCE CHARACTERISTICS:
#pairs (A) LENGTH: 18 base
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:
# 18 CC
- (2) INFORMATION FOR SEQ ID NO:23:
- (i) SEQUENCE CHARACTERISTICS:
#pairs (A) LENGTH: 43 base
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:
# 43 ACTA TAGGGAGAGC TGACAACGCG TCC
- (2) INFORMATION FOR SEQ ID NO:24:
- (i) SEQUENCE CHARACTERISTICS:
#pairs (A) LENGTH: 25 base
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:
# 25 TCGA CATGC
- (2) INFORMATION FOR SEQ ID NO:25:
- (i) SEQUENCE CHARACTERISTICS:
#pairs (A) LENGTH: 25 base
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:
# 25 TAGG TCGTC
- (2) INFORMATION FOR SEQ ID NO:26:
- (i) SEQUENCE CHARACTERISTICS:
#pairs (A) LENGTH: 54 base
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:
- AATTCTAATA CGACTCACTA TAGGGAGAGG GAACATTGTG GTGGGTAGGT CG - #TC
54
- (2) INFORMATION FOR SEQ ID NO:27:
- (i) SEQUENCE CHARACTERISTICS:
#pairs (A) LENGTH: 25 base
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:
# 25 CCTA TACCA
- (2) INFORMATION FOR SEQ ID NO:28:
- (i) SEQUENCE CHARACTERISTICS:
#pairs (A) LENGTH: 25 base
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:
# 25 GGAC AGTCA
__________________________________________________________________________
Claims (21)
1. An oligonucleotide of 10-50 nucleotides, comprising at least 10 consecutive nucleotides of a sequence selected from the group consisting of SEQ ID NO:1 , SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:27, and SEQ ID NO:28,
2. An oligonucleotide comprising the oligonucleotide of claim 1 further comprising the sequence of SEQ ID NO:29 at the 5' end thereof.
3. A method for the detection of HTLV I RNA in a sample, comprising:
a) obtaining a sample which may contain HTLV I RNA;
b) performing isothermal transcription based amplification on the sample with 2 oligonucleotide primers, one of which comprises at least 10 consecutive nucleotides of a sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:15, and SEQ ID NO:16, and the other of which comprises at least 10 consecutive nucleotides of a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:6, SEQ ID NO:10, and SEQ ID NO:14; and
c) detecting the resulting product of step b), whereby detection of the amplification product indicates the presence of HTLV I RNA in the sample.
4. The method of claim 3, wherein the sample comprises cells and RNA is extracted from the cells in the sample prior to step b).
5. The method of claim 3, wherein the detection step uses a labeled probe, wherein the probe comprises a sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13 and SEQ ID NO:17, whereby hybridization of the probe to the amplification product indicates the presence of HTLV I RNA in the sample.
6. A kit for the detection or quantitation of HTLV I RNA in a sample, comprising two primers selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:1, SEQ ID NO:6, SEQ ID NO:10, and SEQ ID NO:14.
7. The kit of claim 6 wherein the primers are SEQ ID NO:1 and SEQ ID NO:3.
8. The kit of claim 6 wherein the primers are SEQ ID NO:6 and SEQ ID NO:8.
9. The kit of claim 6 wherein the primers are SEQ ID NO:10 and SEQ ID NO:12.
10. The kit of claim 6 wherein the primers are SEQ ID NO:14 and SEQ ID NO:16.
11. The kit of claim 6 further comprising, disposed in a separate container, a probe comprising a sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13 and SEQ ID NO:17.
12. The kit of claim 6 wherein the primers are SEQ ID NO:18 and SEQ ID NO:23.
13. The kit of claim 6 wherein the primers are SEQ ID NO:19 and SEQ ID NO:23.
14. The kit of claim 6 wherein the primers are SEQ ID NO:26 and SEQ ID NO:27.
15. A method for the detection of HTLV II RNA in a sample, comprising:
a) obtaining a sample which may contain HTLV II RNA;
b) performing isothermal transcription based amplification on the sample with 2 oligonucleotide primers, one of which comprises at least 10 consecutive nucleotides of a sequence selected from the group consisting of SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:25, and SEQ ID NO:26 and the other of which comprises at least 10 consecutive nucleotides of a sequence selected from the group consisting of SEQ ID NO:18, SEQ ID NO:19, and SEQ ID NO:27; and
c) detecting the resulting product of step b), whereby detection of the amplification product indicates the presence of HTLV II RNA in the sample.
16. The method of claim 15, wherein the sample comprises cells and RNA is extracted from the cells in the sample prior to step b).
17. The method of claim 15, wherein the detection step uses a labeled probe, wherein the probe comprises a sequence selected from the group consisting of SEQ ID NO:24 and SEQ ID NO:28, whereby hybridization of the probe to the amplification product indicates the presence of HTLV II RNA in the sample.
18. A kit for the detection or quantitation of HTLV II RNA in a sample, comprising two primers selected from the group consisting of SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:26 SEQ ID NO:18, SEQ ID NO:19, and SEQ ID NO:27.
19. The kit of claim 18 wherein the primers are SEQ ID NO:18 and SEQ ID NO:21.
20. The kit of claim 18 wherein the primers are SEQ ID NO:19 and SEQ ID NO:21.
21. The kit of claim 18 further comprising, disposed in a separate container, a probe comprising a sequence selected from the group consisting of SEQ ID NO:24 and SEQ ID NO:28.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/015,876 USH1825H (en) | 1998-01-30 | 1998-01-30 | Isothermal transcription based assay for the detection of HTLV I and HTLV II RNA |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/015,876 USH1825H (en) | 1998-01-30 | 1998-01-30 | Isothermal transcription based assay for the detection of HTLV I and HTLV II RNA |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| USH1825H true USH1825H (en) | 1999-12-07 |
Family
ID=21774131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/015,876 Abandoned USH1825H (en) | 1998-01-30 | 1998-01-30 | Isothermal transcription based assay for the detection of HTLV I and HTLV II RNA |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | USH1825H (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060019353A1 (en) * | 1994-01-13 | 2006-01-26 | Enzo Diagnostics, Inc. | Protein-nucleic acid conjugate for producing specific nucleic acid |
| US20110097791A1 (en) * | 1999-04-16 | 2011-04-28 | Engelhardt Dean L | Novel process, construct and conjugate for producing multiple nucleic acid copies |
| WO2016054708A1 (en) * | 2014-10-06 | 2016-04-14 | Fundação Hemocentro de Ribeirão Preto | Oligonucleotides, set of oligonucleotides, htlv-i/htlv-ii infection diagnostic and discrimination kit, polynucleotide suitable as reference target for designing primers and probes for the detection and differentiation of htlv-i and htlv-ii, amplicon and method for detecting at least one htlv target |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5234809A (en) * | 1989-03-23 | 1993-08-10 | Akzo N.V. | Process for isolating nucleic acid |
| US5409818A (en) * | 1988-02-24 | 1995-04-25 | Cangene Corporation | Nucleic acid amplification process |
| US5554517A (en) * | 1988-02-24 | 1996-09-10 | Akzo Nobel N.V. | Nucleic acid amplification process |
-
1998
- 1998-01-30 US US09/015,876 patent/USH1825H/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5409818A (en) * | 1988-02-24 | 1995-04-25 | Cangene Corporation | Nucleic acid amplification process |
| US5554517A (en) * | 1988-02-24 | 1996-09-10 | Akzo Nobel N.V. | Nucleic acid amplification process |
| US5234809A (en) * | 1989-03-23 | 1993-08-10 | Akzo N.V. | Process for isolating nucleic acid |
Non-Patent Citations (32)
| Title |
|---|
| B. Srivastava et al., Cancer Research , 52:4391 4395, 1992. * |
| B. Srivastava et al., Cancer Research, 52:4391-4395, 1992. |
| Bazarbachi et al., Science , 259:1470 1471, 1993. * |
| Bazarbachi et al., Science, 259:1470-1471, 1993. |
| D. Zucker Franklin et al., AIDS Res. and Hum. Retroviruses , 10:9:1173 77, 1994. * |
| D. Zucker-Franklin et al., AIDS Res. and Hum. Retroviruses, 10:9:1173-77, 1994. |
| E. DeFreitas et al., Proc. Natl. Acad. Sci. USA , 88:2922 2926, 1991. * |
| E. DeFreitas et al., Proc. Natl. Acad. Sci. USA, 88:2922-2926, 1991. |
| Frey et al., Schweizer Archiv F u r Tierheilkunde , 138:3:121 124, 1996. * |
| Frey et al., Schweizer Archiv Fur Tierheilkunde, 138:3:121-124, 1996. |
| H. Poteat et al., Journal of Virology , 63:4:1604 1611, 1989. * |
| H. Poteat et al., Journal of Virology, 63:4:1604-1611, 1989. |
| J. Blomberg et al., Journal of AIDS , 5:294 302, 1992. * |
| J. Blomberg et al., Journal of AIDS, 5:294-302, 1992. |
| J. Green et al., Nature , 341:72 74, 1989. * |
| J. Green et al., Nature, 341:72-74, 1989. |
| J. Romano et al., Immunological Investigations , 26(1&2):15 28, 1997. * |
| J. Romano et al., Immunological Investigations, 26(1&2):15-28, 1997. |
| N. Manca et al., J. Exp. Med. , 180:1973 1978, 1994. * |
| N. Manca et al., J. Exp. Med., 180:1973-1978, 1994. |
| P. Tuke et al., Journal of Virological Methods , 40:163 174, 1992. * |
| P. Tuke et al., Journal of Virological Methods, 40:163-174, 1992. |
| R. Grassmann et al., Proc. Natl. Acad. Sci. USA , 86:3351 3355, 1989. * |
| R. Grassmann et al., Proc. Natl. Acad. Sci. USA, 86:3351-3355, 1989. |
| V. Kalyanaraman et al., Science , 218:571 573, 1982. * |
| V. Kalyanaraman et al., Science, 218:571-573, 1982. |
| V. Kalyanaraman et al., The EMBO Journal , 4:6:1455 1460, 1985. * |
| V. Kalyanaraman et al., The EMBO Journal, 4:6:1455-1460, 1985. |
| W. Hall et al., Science , 253:317 320, 1991. * |
| W. Hall et al., Science, 253:317-320, 1991. |
| Z. Berneman et al., Proc. Natl. Acad. Sci. USA , 89:3005 3009, 1992. * |
| Z. Berneman et al., Proc. Natl. Acad. Sci. USA, 89:3005-3009, 1992. |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060019353A1 (en) * | 1994-01-13 | 2006-01-26 | Enzo Diagnostics, Inc. | Protein-nucleic acid conjugate for producing specific nucleic acid |
| US20090068731A1 (en) * | 1994-01-13 | 2009-03-12 | Enzo Biochem, Inc. | Novel process, construct and conjugate for producing multiple nucleic acid copies |
| US20110097791A1 (en) * | 1999-04-16 | 2011-04-28 | Engelhardt Dean L | Novel process, construct and conjugate for producing multiple nucleic acid copies |
| WO2016054708A1 (en) * | 2014-10-06 | 2016-04-14 | Fundação Hemocentro de Ribeirão Preto | Oligonucleotides, set of oligonucleotides, htlv-i/htlv-ii infection diagnostic and discrimination kit, polynucleotide suitable as reference target for designing primers and probes for the detection and differentiation of htlv-i and htlv-ii, amplicon and method for detecting at least one htlv target |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100615407B1 (en) | Nucleic acid sequences that can be used as primers and probes in the amplification and detection of all subtypes of hiv-1 | |
| JP5205346B2 (en) | HIV-1 amplification and detection reagents | |
| US6333150B1 (en) | Isothermal transcription based assay for the detection and genotyping of dengue virus | |
| US20100216117A1 (en) | Oligonucleotides, use, method of detection and kit for diagnosing the presence of the chikungunya virus e1 gene | |
| US6010847A (en) | Oligonucleotides that can be used in the amplification and detection of CMV nucleic acid | |
| USH1825H (en) | Isothermal transcription based assay for the detection of HTLV I and HTLV II RNA | |
| EP0729518B1 (en) | Primers and probes for the amplification and detection of cmv nucleic acid | |
| EP0973948B1 (en) | Nucleic acid based detection of cytomegalovirus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: AKZO NOBEL N.V., NETHERLANDS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ROMANO, JOSEPH W.;SHURTLIFF, ROXANNE;WILLIAMS, KIMBERLY G.;REEL/FRAME:009327/0779 Effective date: 19980205 |
|
| STCF | Information on status: patent grant |
Free format text: PATENTED CASE |